FDA Concerns Are the Least of These Drugs' Worries

Adverse cognitive effect fears shouldn't derail the new class of cholesterol drugs, but Zetia might.

Mar 17, 2014 at 9:30AM

The race to develop a highly effective cholesterol lowering therapy for patients unable to take statins continues, despite some setbacks. A recent revelation prompted a little panic selling, but a bigger event is looming around the corner. There are much bigger concerns for the new drug class that revolve around an unrelated trial with Merck's (NYSE:MRK) market stage cholesterol therapies. 

Late last week, investors noticed a particularly disturbing piece of news in Sanofi's (NYSE:SNY) annual SEC filing. Sanofi and partner Regeneron (NASDAQ:REGN) "have been advised by the FDA that it has become aware of neurocognitive adverse events in the PCSK9 inhibitor class." The disclosure goes on to state that neurocognitive adverse events have been associated with the use of statins, but Sanofi doesn't know of any associated with its PCSK9 inhibitor, alirocumab. The agency also wants Sanofi and Regeneron to basically look into it, and consider including neurocognitive testing into subsets of patients in existing trials.

Although the statement seemed fairly benign, shares of Regeneron fell nearly 10% almost immediately after the news spread quickly over Twitter. Regeneron regained much of what it lost in the panic, as did competitor in the PCSK9 race Amgen (NASDAQ:AMGN). Also investing heavily in PCSK9 therapy is Pfizer (NYSE:PFE), which was relatively unaffected by the news.

REGN Chart

REGN data by YCharts

A fuzzy feeling
As far as adverse events go, the reports of cognitive impairment that the FDA noted in a consumer report updated earlier this year are minor. Other rarely reported statin issues in the agency's update include risk of diabetes and liver injury.

Apparently the regulator has been following rare cases of cognitive impairment that span all statin products for some time now. Patients affected report feeling "fuzzy" or unfocused. Luckily, the feelings are reversible following cessation of treatment.

A more serious concern
While adverse events of any nature should be a cause for concern, the knee-jerk response to such a benign statement illustrates the heavy anxiety surrounding this new drug class. I think the largest risk factor to companies developing PCSK9 therapies is skepticism surrounding the association of lower LDL cholesterol -- the bad kind -- and risk of heart attack or stroke.

At the moment, the FDA is willing to accept reductions in LDL cholesterol as a surrogate endpoint for long-term cardiovascular benefit. This means that companies like Amgen and Sanofi won't be required to monitor patients for years longer than planned.

Unfortunately for the companies, those rules aren't set in stone. If the agency changes its mind, drugmakers will need to pay for lengthy cardiac outcome studies to determine whether or not patients receiving PCSK9 injections actually suffer heart attack or stroke at significantly lower rates.

An important release
Last November, deputy director of the FDA's division of metabolism and endocrinology Eric Colman told Bloomberg that the agency is waiting on results of an extremely long trial, titled Improve-it. The trial, initiated in 2005, is comparing Merck's Vytorin (ezetimibe/simvastatin) to Zetia (ezetimibe). While Zetia is proven to lower LDL cholesterol in patients who can't take statins, its effect on overall risk of cardiac events is still considered unproven.

Since PCSK9 injections are also intended for patients that can't take statins, the results of this trial, expected this September, might be the event of the year. If ezetimibe doesn't significantly lower the risk of cardiac events, the fallout from Sanofi's recent disclosure may pale in comparison.

In 2008, the controversial Enhance study suggested that the combination of simvastatin and ezetimibe did not result in significant differences in thickness of inner-arterial walls compared to simvastatin alone. It's hardly a death-blow for non-statin LDL cholesterol lowering therapies, but it doesn't inspire confidence either. Pfizer has already hedged its bet on its PCSK9 candidate by initiating cardiac outcomes trials. This September Pfizer's competitors may wish they did as well.

Stop worrying about the day to day
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers